Valeant Pharmaceuticals International Inc. (VRX.T) and Bill
Ackman's Pershing Square have filed a complaint with the Securities
and Exchange Commission over claims that Allergan has been
misleading investors by making false and misleading statements
about Valeant, CNBC reported Monday.
Specifically, Valeant is objecting to Allergan claims that
Valeant has stagnant or declining sales in its Bausch and Lomb
business unit, CNBC said.
Robert Khuzami, former head of enforcement of the SEC, is
leading the effort for Valeant and Pershing Square, the report
said, and separately they have gone to regulators in Quebec to file
complaints.
Full story at www.cnbc.com
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires